Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.46 |
| ▸ | JAK3 | P52333 | 7/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 13/20 | 0.45 |
| ▸ | CHUK | O15111 | 5/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | PLK1 | P53350 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | ITK | Q08881 | 1/20 | 0.45 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2767537 | 0.72 | IKBKB (0.63) | JAK2JAK3JAK1TYK2IKBKB | |
| SCHEMBL2768509 | 0.71 | IKBKB (0.63) | IKBKBCHUK | |
| SCHEMBL2768202 | 0.70 | IKBKB (0.69) | IKBKBCHUK | |
| SCHEMBL2769215 | 0.70 | IKBKB (0.65) | IKBKBCHUK | |
| SCHEMBL2767468 | 0.69 | IKBKB (0.65) | IKBKBCHUK | |
| SCHEMBL2768094 | 0.69 | IKBKB (0.81) | IKBKBCHUK | |
| SCHEMBL2767493 | 0.69 | IKBKB (0.81) | IKBKBCHUK | |
| SCHEMBL14589355 | 0.68 | IKBKB (0.68) | JAK2TYK2IKBKBCHUKCDK2 | |
| SCHEMBL3039775 | 0.68 | IKBKB (0.74) | IKBKBCHUK | |
| SCHEMBL2768187 | 0.68 | IKBKB (0.54) | JAK2JAK3JAK1TYK2IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737279-B2 | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-15 | — | — | US | disclosed |
| US-20060270654-A1 | 1,6-Dihydro-1,3,5,6-Tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270654-A1 | 1,6-Dihydro-1,3,5,6-Tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | IL1R1, IDO1, TLR1 | JAK2 681/4885JAK3 1250/4885JAK1 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.